Topical Ruxolitinib 1.5% for Hidradenitis Suppurativa Treatment

Inclusion criteria

• ✓. Male or female subjects age 12 years or older
• ✓. Hidradenitis suppurativa, and should be Hurley Stage I or II, defined as papules, nodules, and/or abscess formation, single or multiple, with or without sinus tracts;
• ✓. Subjects must have a diagnosis of HS for at least 3 months (90 days) prior to Baseline;
• ✓. Active HS lesions must be present in at least one distinct anatomic area;
• ✓. Subject must have at least 3 total inflammatory lesions at the Baseline visit;
• ✓. Subjects who had surgery in the treatment area, should be at least 3 months status post the procedure (this applies to deroofing/marsupialization or excision, not incision \& drainage)
• ✓. Subject has a negative TB screening assessment (including a PPD test and/or Quantiferon-TB Gold test equivalent) OR for patients with treated latent TB or negative chest x-ray (CXR posterior-anterior \[PA\] and lateral view within prior 90 days) at Screening with documentation of treated latent tuberculosis (90 days of treatment).
• ✓. Medications can be continued if they have been at a stable dose for the requisite duration and the dose is not increased during the study period:

Exclusion criteria